DrugPatentWatch Database Preview

FLOVENT HFA Drug Profile

« Back to Dashboard

Which patents cover Flovent Hfa, and when can generic versions of Flovent Hfa launch?

Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There are sixteen patents protecting this drug.

The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-seven drug master file entries for this compound. Eighty-three suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Summary for FLOVENT HFA

US Patents:	16
Applicants:	1
NDAs:	1
Suppliers / Packagers:	4
Bulk Api Vendors:	64
Clinical Trials:	27
Patent Applications:	4,558
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for FLOVENT HFA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FLOVENT HFA
DailyMed Link:	FLOVENT HFA at DailyMed

Pharmacology for FLOVENT HFA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Synonyms for FLOVENT HFA

(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-14-yl propanoate

(6?,11?,16?,17?)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid fluoromethyl ester

(6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester

[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate

474F142

6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate

80474-14-2

AB00513992

AB00513992_08

AB00513992-06

AB1010912

AC-457

AC1L9FLD

AJ-47435

AKOS015895220

AN-584/43505443

Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester

Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-

ArmonAir RespiClick

ArmonAir RespiClickTM

Asmatil

atemur

Axotide

BC216013

BDBM50354849

BIF0710

BPBio1_001203

BR-72799

BRD-K62310379-001-03-0

Brethal

BSPBio_001093

C25H31F3O5S

CCG-100981

CCI 18781

CCI-18781

CHEBI:31441

CHEMBL1473

CS-1986

Cultivate

Cutivate

Cutivate (TN)

D01708

DB00588

Flixonase

Flixonase Nasal Spray

Flixotide

Flixotide Disk

Flixotide Disks

Flixotide Inhaler

Flonase

Flonase (TN)

Flonase Allergy Relief

Flonase Aq

Flovent

Flovent (TN)

Flovent Diskus

Flovent Diskus 100

Flovent Diskus 250

Flovent Diskus 50

Flovent-hfa

Fluinol

Flunase

Flusonal

Fluspiral

Fluticasone (propionate)

fluticasone 17-propionate

Fluticasone Impurity B

FLUTICASONE PROPIONATE

Fluticasone propionate (Flonase, Veramyst)

Fluticasone propionate (JAN/USAN)

Fluticasone propionate [USAN:USP]

Fluticasone propionate [USAN]

Fluticasone propionate for impurity C identification, EuropePharmacopoeia (EP) Reference Standard

Fluticasone propionate for impurity G identification, EuropePharmacopoeia (EP) Reference Standard

Fluticasone propionate, >=98% (HPLC), powder

Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard

Fluticasone Propionate, pharmaceutical secondary standard; traceable to USP, PhEur, BP

Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard

fluticasone proprionate

Fluticasonpropionat Allen

Flutide

Flutivate

Fluxonal

FN-25

FT-0082893

GTPL7080

HMS1571G15

HMS2051N19

HMS2098G15

HY-B0154

Inalacor

KS-1173

LS-19323

MFCD00866007

MLS001424085

MolPort-003-847-468

NC00231

NCGC00179308-01

NCGC00179308-05

O2GMZ0LF5W

Prestwick0_000997

Prestwick1_000997

Prestwick2_000997

Prestwick3_000997

Q-101393

Rinosone

RS0009

S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate

S-(fluoromethyl)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate,17-propionate

s1992

SBB071021

SC-19333

SCHEMBL4068

Skyron

SMR000469159

SPBio_002984

ST2407016

Trialona

Ubizol

UNII-O2GMZ0LF5W

WMWTYOKRWGGJOA-CENSZEJFSA-N

Xhance

ZINC3920027

Zoflut

US Patents and Regulatory Information for FLOVENT HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004		RX	Yes	Yes			Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-002	May 14, 2004		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-002	May 14, 2004		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-003	May 14, 2004		RX	Yes	Yes			Y

Expired US Patents for FLOVENT HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-003	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-003	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-002	May 14, 2004
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-001	May 14, 2004

International Patents for FLOVENT HFA

Country	Document Number	Estimated Expiration
Czech Republic	9902323
Japan	4686661
Poland	337316
Canada	2415297
Yugoslavia	29899
South Africa	200409592
Spain	2321601

Supplementary Protection Certificates for FLOVENT HFA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0014	France		PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215